Peptides DB
Research-centric peptide and protocol reference hub
Study 3 of 3Ribupatide literatureClinical drug investigation · Observational2024

An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients.

The study suggests that 180 mg RBP-7000 is well tolerated in stable schizophrenia patients previously on oral risperidone, but further research is needed to confirm these findings.

Read at Clinical drug investigationAdd to compare

Where it sits

this study against the rest of the ribupatide corpus
0
Preclinical
1
Observational · this one
0
Open-label
2
Randomised
0
Reviews

Summary and findings

This study assessed the pharmacokinetics and tolerability of 180 mg RBP-7000 in stable schizophrenic patients previously on 6 mg/day oral risperidone. A total of 23 participants received at least one dose, with 15 completing the study. Results indicated similar average plasma concentrations of risperidone between the two administration methods.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2024

Abstract

The authors’ words, as Clinical drug investigation supplied them

<h4>Background and objective</h4>Long-acting injectable antipsychotics have shown benefits over oral medications with reduced hospitalization rates and improved health-related quality of life. RBP-7000 (PERSERIS<sup>®</sup>) is a monthly risperidone formulation (90 or 120 mg) for the treatment of schizophrenia administered by subcutaneous abdominal injection. The objective of this study was to assess a higher dose of 180 mg RBP-7000 and an alternate injection site.<h4>Methods</h4>Following stabilization on 6 mg/day (3 mg twice daily) oral risperidone, clinically stable schizophrenic participants received 3 monthly doses of 180 mg RBP-7000 in the abdomen followed by a fourth monthly dose of 180 mg RBP-7000 in the upper arm (each dose administered as two 90-mg injections). The primary endpoint was the steady-state average plasma concentration (C<sub>avg(ss)</sub>) of risperidone and total active moiety after oral and RBP-7000 administration. Secondary endpoints included measures of clinical efficacy (Positive and Negative Syndrome Scale, Clinical Global Impression Scale for Severity of Illness), safety, and local injection-site tolerability to assess the switch from oral risperidone and compare injection sites.<h4>Results</h4>In all, 23 participants received at least one dose of RBP-7000, 16 received all four doses, and 15 completed the study. Monthly doses of 180 mg RBP-7000 provided similar C<sub>avg(ss)</sub> of total active moiety compared with 6 mg/day oral risperidone. The pharmacokinetics of RBP-7000 were similar after injection in the abdomen versus upper arm. Clinical efficacy measures remained stable throughout the study. All RBP-7000 injections were well tolerated with no unexpected safety findings.<h4>Conclusions</h4>The results support the use of 180 mg RBP-7000 in schizophrenic patients stable on 6 mg/day oral risperidone and a second injection site in the upper arm.<h4>Trial registration</h4>ClinicalTrials.gov identifier: NCT03978832.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Ribupatide corpus

APreclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.Diabetes, obesity & metabolism · 2023 · n=90 · Mean weight change in ribupatide groups ranged from -4.3 kg (-6.7%) to -7.7 kg (-9.6%), compared with -1.2 kg (-1.4%) in the placebo group.reviewDPreclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.Diabetes, obesity & metabolism · 2026 · Mean weight change in ribupatide groups ranged from -4.3 kg (-6.7%) to -7.7 kg (-9.6%) after four weekly doses, compared with -1.2 kg (-1.4%) in the placebo group.review